Nocturia

Nocturia is associated with sleep disturbance and depressive symptoms, but the role of daytime sleepiness in this relationship remains unclear. This study examined the relationships among nocturia, sleep duration, daytime sleepiness, and depressive symptoms, with particular attention to the indirect associations through sleep duration and daytime sleepiness.

We thank the authors for their thoughtful comments on our multicenter cohort study examining the association between aging and nocturnal polyuria in patients with nocturia.

We agree that fluid intake, sleep status, renal function, lower extremity edema, comorbidities, and concomitant medications are important factors in evaluating nocturnal polyuria, particularly in older adults.

To clarify the characteristics of co-existent overactive and underactive bladder (COUB) in participants with nocturia from the 2023 Japan Community Health Survey.

Participants reporting nocturia (≥1 episode per night) were divided into four groups: COUB, overactive bladder (OAB) alone, underactive bladder (UAB) alone, and neither OAB nor UAB (non-OAB/UAB).

Insomnia and nocturia are prevalent, highly comorbid conditions and share a mutual connection. We aim to further elucidate the link between both in order to improve sleep and eventually overall health.

Although the prevalence of nocturnal polyuria (NP) increases with age, the mechanisms underlying age-related changes in voiding patterns and the daytime-nighttime distribution of urine volume remain unclear.

Desmopressin is an established treatment for nocturia due to nocturnal polyuria. In Japan, low-dose formulations (25 and 50 μg) were approved only for men in 2019. However, age- and dose-specific prescribing patterns in real-world practice remain unclear.

Background and Objectives: Overactive bladder (OAB) is frequently associated with impaired quality of life and sleep disturbances, particularly in women with refractory symptoms. Non-invasive neuromodulation targeting autonomic regulation has emerged as a potential therapeutic approach.

To investigate the prevalence and factors associated with nocturia, defined as ≥ 2 times/night, among participants from the 2023 Japan Community Health Survey (JaCS 2023).

Using data from JaCS 2023, a nationwide online survey comprising 48 questionnaire items on lower urinary tract symptoms and daily life, 6210 participants aged 20-99 years were evaluated.

Nocturia is a common symptom among adults and is often associated with disrupted sleep and diminished quality of life. In many cases, it is driven by nocturnal polyuria, an imbalance in nighttime urine production.

To investigate the efficacy of desmopressin in older men with persistent nocturia due to nocturnal polyuria and then determine the independent factors affecting the efficacy of desmopressin.

Desmopressin 50 mg was administered for 12 weeks to 49 patients (76.